Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $81.9M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnova.... |
| - | CARB-X | carb-x.org |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.09.2017 | Series B | $31.9M | - |
| 04.04.2016 | Series B | $50M | - |
Mentions in press and media 20
| Date | Title | Description |
| 09.06.2022 | Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference | WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced m... |
| 24.05.2022 | Klarna layoffs signal trouble ahead for unicorns—and consumers | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s happening. Paid Content How does ESG investment push innovation within a company From Northr... |
| 17.05.2022 | Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference | WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced th... |
| 27.04.2022 | Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update | Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conference SUL-DUR NDA submission on track for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now antici... |
| 26.04.2022 | Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference | WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced ... |
| 18.04.2022 | Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference | WALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced ... |
| 03.03.2022 | Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update | Phase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 ... |
| 03.02.2022 | Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc. | WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that i... |
| 02.02.2022 | Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc. | WALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that i... |
| 10.01.2022 | Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022 | WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced t... |
Show more